Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block in Heart Failure
NCT01509651Phase 3Completed
- Sponsor
- OLV Hospital
- Start
- Jan 2012
- Primary completion
- Mar 2012
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Sugammadex in neuromuscular blockade (NMB), sponsored by OLV Hospital. Started Jan 2012; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT01509651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01509651.